A CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA considered the ability and incentive of the merging parties to increase the price of a branded pharmaceutical following the merger. Aspects of this consideration included setting out the features of list and net pricing of branded drugs in the Canadian pharmaceutical marketplace, and the various constraints and factors that bear on those prices.
IP Literature Watch: September 2022
Among the pieces featured in this month’s IP Literature Watch are a paper discussing the licensing of 5G SEPs by automotive manufacturers; an essay exposing...